These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
233 related articles for article (PubMed ID: 32282698)
1. Association of clopidogrel high on-treatment reactivity with clinical outcomes and gene polymorphism in acute ischemic stroke patients: An observational study. Fu H; Hu P; Ma C; Peng F; He Z Medicine (Baltimore); 2020 Apr; 99(15):e19472. PubMed ID: 32282698 [TBL] [Abstract][Full Text] [Related]
2. The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation. Liang ZY; Han YL; Zhang XL; Li Y; Yan CH; Kang J EuroIntervention; 2013 Jul; 9(3):316-27. PubMed ID: 23872648 [TBL] [Abstract][Full Text] [Related]
3. Clopidogrel responder status is uninfluenced by CYP2C19*2 in Danish patients with stroke. Rath CL; Jørgensen NR; Wienecke T PLoS One; 2020; 15(12):e0236260. PubMed ID: 33370281 [TBL] [Abstract][Full Text] [Related]
4. Genotype Frequencies of CYP2C19, P2Y12 and GPIIIa Polymorphisms in Coronary Heart Disease Patients of Han Ethnicity, and Their Impact on Clopidogrel Responsiveness. Ou W; He Y; Li A; Liu B; Jin L Int Heart J; 2016 Sep; 57(5):586-92. PubMed ID: 27488401 [TBL] [Abstract][Full Text] [Related]
5. Influence of CYP2C19 polymorphisms on platelet reactivity and clinical outcomes in ischemic stroke patients treated with clopidogrel. Qiu LN; Sun Y; Wang L; Han RF; Xia XS; Liu J; Li X Eur J Pharmacol; 2015 Jan; 747():29-35. PubMed ID: 25489921 [TBL] [Abstract][Full Text] [Related]
6. High On-Treatment Platelet Reactivity as Predictor of Long-term Clinical Outcomes in Stroke Patients with Antiplatelet Agents. Lv H; Yang Z; Wu H; Liu M; Mao X; Liu X; Ding H; Shi Z; Zhou Y; Liu Q; Zhang Y; Zhou Y; Chen K; Li Z; Dong Q; Ma J; Han Y Transl Stroke Res; 2022 Jun; 13(3):391-398. PubMed ID: 34596891 [TBL] [Abstract][Full Text] [Related]
7. Association between platelet function and recurrent ischemic vascular events after TIA and minor stroke . Zhang J; Zhang J; Sun H; Ming T; Liu X; Cong Y; Li F; Li Z Int J Clin Pharmacol Ther; 2017 Oct; 55(10):789-797. PubMed ID: 28766499 [TBL] [Abstract][Full Text] [Related]
8. Influence of Genetic Polymorphisms on Clopidogrel Response and Clinical Outcomes in Patients with Acute Ischemic Stroke CYP2C19 Genotype on Clopidogrel Response. Han Y; Lv HH; Liu X; Dong Q; Yang XL; Li SX; Wu S; Jiang JM; Luo Z; Zhu DS; Zhang Y; Zheng Y; Guan YT; Xu JF CNS Neurosci Ther; 2015 Sep; 21(9):692-7. PubMed ID: 26177117 [TBL] [Abstract][Full Text] [Related]
9. Genotyping-guided approach versus the conventional approach in selection of oral P2Y12 receptor blockers in Chinese patients suffering from acute coronary syndrome. Tam CC; Kwok J; Wong A; Yung A; Shea C; Kong SL; Tang WH; Siu D; Chan R; Lee S J Int Med Res; 2017 Feb; 45(1):134-146. PubMed ID: 28222641 [TBL] [Abstract][Full Text] [Related]
10. A study of microRNA-223 in evaluating platelet reactivity in patients with acute ischemic stroke. Wang DL; Li X; Wang RN; Sun Y; Xia XS; Tian WJ; Wang L J Physiol Pharmacol; 2022 Feb; 73(1):. PubMed ID: 35793763 [TBL] [Abstract][Full Text] [Related]
11. Impact of CYP2C19 Polymorphisms on Clinical Outcomes and Antiplatelet Potency of Clopidogrel in Caucasian Poststroke Survivors. Tomek A; Matʼoška V; Frýdmanová A; Magerová H; Šrámek M; Paulasova-Schwabová J; Růžičková T; Janský P; Šarbochová I; Hadačová I; Kaplan V; Lacinová Z; Táborský L; Serebruany V Am J Ther; 2018; 25(2):e202-e212. PubMed ID: 29509167 [TBL] [Abstract][Full Text] [Related]
12. CYP2C19*2 and Other Allelic Variants Affecting Platelet Response to Clopidogrel Tested by Thrombelastography in Patients with Acute Coronary Syndrome. Liu J; Nie XY; Zhang Y; Lu Y; Shi LW; Wang WM Chin Med J (Engl); 2015 Aug; 128(16):2183-8. PubMed ID: 26265611 [TBL] [Abstract][Full Text] [Related]
13. CYP2C19 and CES1 polymorphisms and efficacy of clopidogrel and aspirin dual antiplatelet therapy in patients with symptomatic intracranial atherosclerotic disease. Hoh BL; Gong Y; McDonough CW; Waters MF; Royster AJ; Sheehan TO; Burkley B; Langaee TY; Mocco J; Zuckerman SL; Mummareddy N; Stephens ML; Ingram C; Shaffer CM; Denny JC; Brilliant MH; Kitchner TE; Linneman JG; Roden DM; Johnson JA J Neurosurg; 2016 Jun; 124(6):1746-51. PubMed ID: 26587656 [TBL] [Abstract][Full Text] [Related]
14. The association between high on-treatment platelet reactivity and early recurrence of ischemic events after minor stroke or TIA. Rao Z; Zheng H; Wang F; Wang A; Liu L; Dong K; Zhao X; Wang Y; Cao Y Neurol Res; 2017 Aug; 39(8):719-726. PubMed ID: 28398139 [TBL] [Abstract][Full Text] [Related]
15. [Relationship between clopidogrel resistance and genetic variability in Kawasaki disease children with coronary artery lesions]. Cao YY; Pan QY; Li J; Zhong XF; Liang XC; He L; Chu C; Zhao QM; Zhao L; Wang F; Sun SN; Lin YX; Huang GY; Liu F Zhonghua Er Ke Za Zhi; 2024 Oct; 62(10):981-988. PubMed ID: 39327966 [No Abstract] [Full Text] [Related]
16. Impact of genetic variants on post-clopidogrel platelet reactivity in patients after elective percutaneous coronary intervention. Rideg O; Komócsi A; Magyarlaki T; Tokés-Füzesi M; Miseta A; Kovács GL; Aradi D Pharmacogenomics; 2011 Sep; 12(9):1269-80. PubMed ID: 21806387 [TBL] [Abstract][Full Text] [Related]
17. Haplotype of platelet receptor P2RY12 gene is associated with residual clopidogrel on-treatment platelet reactivity. Nie XY; Li JL; Zhang Y; Xu Y; Yang XL; Fu Y; Liang GK; Lu Y; Liu J; Shi LW J Zhejiang Univ Sci B; 2017 Jan.; 18(1):37-47. PubMed ID: 28070995 [TBL] [Abstract][Full Text] [Related]
18. CRISPLD1 rs12115090 polymorphisms alters antiplatelet potency of clopidogrel in coronary artery disease patients in Chinese Han. Wang JY; Zhang YJ; Li H; Hu XL; Li MP; Song PY; Ma QL; Peng LM; Chen XP Gene; 2018 Dec; 678():226-232. PubMed ID: 30096456 [TBL] [Abstract][Full Text] [Related]
19. Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study. Kim IS; Jeong YH; Park Y; Yoon SE; Kwon TJ; Park JR; Hwang SJ; Koh EH; Kwak CH; Hwang JY; Kim S Br J Clin Pharmacol; 2012 Apr; 73(4):629-40. PubMed ID: 22007612 [TBL] [Abstract][Full Text] [Related]
20. Variant recurrent risk among stroke patients with different CYP2C19 phenotypes and treated with clopidogrel. Sun W; Li Y; Li J; Zhang Z; Zhu W; Liu W; Cai Q; Wang X; Cao L; Bai W; Fan X; Ma M; Guo R; Liu X; Xu G Platelets; 2015; 26(6):558-62. PubMed ID: 25207801 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]